Unnatural Polyketide Analogues Selectively Target the HER Signaling Pathway in Human Breast Cancer Cells
- 19 February 2010
- journal article
- research article
- Published by Wiley in ChemBioChem
- Vol. 11 (4), 573-580
- https://doi.org/10.1002/cbic.200900674
Abstract
Receptor tyrosine kinases are critical targets for the regulation of cell survival. Cancer patients with abnormal receptor tyrosine kinases (RTK) tend to have more aggressive disease with poor clinical outcomes. As a result, human epidermal growth factor receptor kinases, such as EGFR (HER1), HER2, and HER3, represent important therapeutic targets. Several plant polyphenols including the type III polyketide synthase products (genistein, curcumin, resveratrol, and epigallocatechin‐3‐galate) possess chemopreventive activity, primarily as a result of RTK inhibition. However, only a small fraction of the polyphenolic structural universe has been evaluated. Along these lines, we have developed an in vitro route to the synthesis and subsequent screening of unnatural polyketide analogues with N‐acetylcysteamine (SNAc) starter substrates and malonyl‐coenzyme A (CoA) and methylmalonyl‐CoA as extender substrates. The resulting polyketide analogues possessed a similar structural polyketide backbone (aromatic‐2‐pyrone) with variable side chains. Screening chalcone synthase (CHS) reaction products against BT‐474 cells resulted in identification of several trifluoromethylcinnamoyl‐based polyketides that showed strong suppression of the HER2‐associated PI3K/AKT signaling pathway, yet did not inhibit the growth of nontransformed MCF‐10A breast cells (IC50>100 μM ). Specifically, 4‐trifluoromethylcinnamoyl pyrone (compound 2 e ) was highly potent (IC50M ) among the test compounds toward proliferation of several breast cancer cell lines. This breadth of activity likely stems from the ability of compound 2 e to inhibit the phosphorylation of HER1, HER2, and HER3. Therefore, these polyketide analogues might prove to be useful drug candidates for potential breast cancer therapy.Keywords
This publication has 55 references indexed in Scilit:
- In Vitro Precursor-Directed Synthesis of Polyketide Analogues with Coenzyme A Regeneration for the Development of Antiangiogenic AgentsOrganic Letters, 2009
- Effect of Lapatinib on the Development of Estrogen Receptor–Negative Mammary Tumors in MiceJNCI Journal of the National Cancer Institute, 2009
- Multi-targeted therapy of cancer by genisteinCancer Letters, 2008
- A Unified Synthetic Approach to Polyketides Having Both Skeletal and Stereochemical DiversityOrganic Letters, 2007
- Exploiting the PI3K/AKT Pathway for Cancer Drug DiscoveryNature Reviews Drug Discovery, 2005
- ERBB receptors and cancer: the complexity of targeted inhibitorsNature Reviews Cancer, 2005
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProceedings of the National Academy of Sciences, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Cancer chemoprevention with dietary phytochemicalsNature Reviews Cancer, 2003
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987